Agonists of parathyroid hormone 1 and incretin receptors

Small molecule compounds targeting PTH1R and modulating GLP-1R, GIPR, and GCGR stimulate bone formation and treat osteoporosis and related conditions, providing improved therapeutic outcomes for osteoporosis, diabetes, and obesity.

WO2026112419A1PCT designated stage Publication Date: 2026-05-28SEPTERNA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/056547
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-10-29
Filing Date
2025-11-21
Publication Date
2026-05-28

AI Technical Summary

Technical Problem

Current treatments for osteoporosis and related conditions, such as osteoporosis, diabetes, obesity, and heart disease, do not effectively stimulate new bone formation or improve bone mass and strength, and existing GLP-1R agonists are not sufficiently efficacious for these conditions.

Method used

Development of small molecule compounds that act as PTH1R agonists and modulators of GLP-1R, GIPR, and GCGR to stimulate bone formation and treat conditions like osteoporosis, diabetes, obesity, and heart disease.

Benefits of technology

The compounds provide a therapeutic approach to stimulate new bone formation and improve bone mass and strength, offering more efficacious treatment options for osteoporosis and addressing conditions like diabetes and obesity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000004_0002
    Figure IMGF000004_0002
Patent Text Reader

Abstract

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.
Need to check novelty before this filing date? Find Prior Art